IRIS
DELLA PORTA, MATTEO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.148
EU - Europa 913
AS - Asia 543
AF - Africa 164
SA - Sud America 29
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 6.812
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.097
FI - Finlandia 282
CN - Cina 235
SG - Singapore 211
IE - Irlanda 198
NG - Nigeria 159
FR - Francia 88
DE - Germania 82
NL - Olanda 61
IT - Italia 57
CA - Canada 49
SE - Svezia 44
GB - Regno Unito 43
IN - India 22
TR - Turchia 21
BR - Brasile 18
BE - Belgio 17
JP - Giappone 16
AU - Australia 10
ES - Italia 10
IR - Iran 9
HK - Hong Kong 8
RU - Federazione Russa 7
CL - Cile 6
CH - Svizzera 5
IL - Israele 4
ZA - Sudafrica 4
AT - Austria 3
DK - Danimarca 3
NO - Norvegia 3
PH - Filippine 3
BD - Bangladesh 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
EU - Europa 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
TH - Thailandia 2
UA - Ucraina 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BO - Bolivia 1
GR - Grecia 1
HU - Ungheria 1
ID - Indonesia 1
KR - Corea 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
PA - Panama 1
PE - Perù 1
PL - Polonia 1
RO - Romania 1
SI - Slovenia 1
VN - Vietnam 1
Totale 6.812
Salva come PNG Salva come JPEG
Città #
Wilmington 1.026
Chandler 954
San Mateo 356
Helsinki 282
Ann Arbor 246
Shanghai 198
Dublin 197
Boardman 185
Leawood 165
Benin City 159
Lawrence 159
Princeton 159
Singapore 149
Woodbridge 121
Ashburn 114
Fairfield 101
New York 101
Paris 86
Amsterdam 59
Houston 41
Toronto 36
Seattle 32
London 30
Cambridge 23
Falls Church 23
Norwalk 22
Kocaeli 18
San Diego 18
Brussels 17
Redwood City 17
Los Angeles 15
Milan 15
Monmouth Junction 15
Beijing 14
Santa Clara 13
Tokyo 13
São Paulo 12
Redmond 11
Pune 9
San Francisco 9
Tappahannock 9
Mumbai 6
Abbiategrasso 5
Genoa 5
Phoenix 5
Des Moines 4
Falkenstein 4
Frankfurt am Main 4
Clearwater 3
Leinfelden-echterdingen 3
Manila 3
Nashville 3
San Jose 3
Urmia 3
Bangkok 2
Barcelona 2
Berlin 2
Bhubaneswar 2
Boulder 2
Canberra 2
Cary 2
Central District 2
Charlotte 2
Chesterfield 2
Hackney 2
Hanover 2
Hefei 2
Huntington 2
Jamaica Plain 2
Johnson City 2
Las Vegas 2
Mandi 2
Melbourne 2
Morbegno 2
Moscow 2
Oslo 2
Pittsburgh 2
Quito 2
Röllbach 2
Sevilla 2
Shenzhen 2
Stockholm 2
Tulsa 2
Vancouver 2
Vienna 2
Vientiane 2
Wuhan 2
Yokohama 2
Alba 1
Almaty 1
Athens 1
Auckland 1
Bellville 1
Bergamo 1
Boston 1
Brno 1
Buccinasco 1
Cagliari 1
Cape Town 1
Central 1
Totale 5.360
Salva come PNG Salva come JPEG
Nome #
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 183
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun. 2015 Jan 9;6:5901. 108
Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. 83
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group 83
Carenza C, Calcaterra F, Oriolo F, Di Vito C, Ubezio M, Della Porta MG, Mavilio D, Della Bella S. 74
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 70
CD34 and CD2 expression in acute promyelocytic leukemia. 59
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? 59
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. 58
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 58
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 56
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 56
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 56
Classification and prognostic evaluation of myelodysplastic syndromes 55
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) 54
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 53
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 52
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 52
Leukemic transformation of polycythemia vera: a single center study of 23 patients 51
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 51
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. 51
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. 50
Hematologic responses with deferasirox therapy in transfusion-dependent myelodysplastic syndromes patients. 50
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 50
Dendritic cells in acute promyelocytic leukaemia. 49
Prognosis of secondary acute myeloid leukemia 49
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 49
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 49
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 49
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 49
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006 Nov 1;107(9):2206-11. PubMed PMID: 16998940. 49
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. 49
Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. 48
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 48
Myelodysplastic syndromes and bone marrow microenvironment. 48
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 48
Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome. 47
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 47
Consolidation treatment with autologous peripheral blood progenitor cell transplantation in acute myeloid leukemia: a single center experience. 47
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. 47
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 47
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia 46
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival 46
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 46
Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients. 45
Clinical and biological implications of driver mutations in myelodysplastic syndromes 45
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. 45
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 45
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 45
Simian virus 40 and lymphoproliferative disorder. 45
High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene. 44
Novel trial designs for high-risk myelodysplastic syndromes. 44
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. 44
Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. 44
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 44
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 44
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 44
Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening. 43
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. 43
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet 43
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 43
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens. 43
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 43
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 43
An unusual clinical presentation of multiple myeloma with involvement of the oro-pharynx. 42
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. 42
Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study 42
Involvement of the region 13q14 in a patient with admantinoma of the long bones 42
Differentiation of follicular dendritic sarcoma cells into functional myeloid-dendritic cell-like elements. 42
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 42
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 41
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. 41
Alterata espressione dei canali del Ca2+ in cellule progenitrici endoteliali di pazienti affetti da carcinoma cellulare renale, mielofibrosi idiopatica e tumore della mammella 41
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 41
The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome 41
Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). 41
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. 41
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 40
Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. 40
Importance of classical morphology in the diagnosis of myelodysplastic syndrome. 40
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 40
Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes. 39
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 39
DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing? 39
Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant. 39
Prognostic models in myelodysplastic syndromes 38
Myelodysplastic syndromes with bone marrow fibrosis. 38
Outcome after allogeneic bone marrow transplantation in cytogenetic high-risk myelodysplastic syndromes and acute myeloid leukemia. 38
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. 38
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 38
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study 37
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 37
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspective. 37
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 36
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. 36
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 36
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. 36
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. 35
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 35
Role of the molecular staging and response in the management of follicular lymphoma patients. 35
Totale 4.813
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.284
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.284
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 0 0 0 0 0 0 0 5
2020/20211.835 20 53 99 10 18 531 242 104 360 220 16 162
2021/20221.059 70 12 24 213 23 26 29 132 105 70 323 32
2022/20232.634 374 85 210 325 252 237 5 234 493 210 176 33
2023/20241.356 121 178 278 47 27 115 57 149 20 46 167 151
2024/202523 23 0 0 0 0 0 0 0 0 0 0 0
Totale 6.912